Anderson Katie L, Modiano Jaime F
DVM/PhD Combined Degree and Comparative Molecular Biosciences Graduate Programs, Department of Veterinary Clinical Sciences, College of Veterinary Medicine and Animal Cancer Care and Research Center, University of Minnesota, St. Paul, MN 55108, USA.
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Animal Cancer Care and Research Center, Center for Immunology, Masonic Cancer Center, and Stem Cell Institute, University of Minnesota, Minneapolis, MN 55108, USA.
Vet Sci. 2015 Dec;2(4):363-387. doi: 10.3390/vetsci2040363. Epub 2015 Oct 19.
Harnessing the ability of the immune system to eradicate cancer has been a long-held goal of oncology. Work from the last two decades has finally brought immunotherapy into the forefront for cancer treatment, with demonstrable clinical success for aggressive tumors where other therapies had failed. In this review, we will discuss a range of therapies that are in different stages of clinical or preclinical development for companion animals with cancer, and which share the common objective of eliciting adaptive, anti-tumor immune responses. Even though challenges remain, manipulating the immune system holds significant promise to create durable responses and improve outcomes in companion animals with cancer. Furthermore, what we learn from this process will inform and accelerate development of comparable therapies for human cancer patients.
利用免疫系统根除癌症一直是肿瘤学长期以来的目标。过去二十年的研究终于使免疫疗法成为癌症治疗的前沿方法,在其他疗法失败的侵袭性肿瘤治疗中取得了显著的临床成功。在这篇综述中,我们将讨论一系列处于临床或临床前不同开发阶段的用于患癌伴侣动物的疗法,这些疗法都有一个共同目标,即引发适应性抗肿瘤免疫反应。尽管挑战依然存在,但操控免疫系统有望为患癌伴侣动物产生持久反应并改善治疗结果。此外,我们从这个过程中学到的知识将为人类癌症患者类似疗法的开发提供信息并加速其发展。